\BOOKMARK [0][-]{section*.4}{Acronyms}{}% 1
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 2
\BOOKMARK [1][-]{section.4.1}{Synthetic lethal genes in breast cancer}{chapter.4}% 3
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic lethal pathways in breast cancer}{section.4.1}% 4
\BOOKMARK [2][-]{subsection.4.1.2}{Expression profiles of synthetic lethal partners}{section.4.1}% 5
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup pathway analysis}{subsection.4.1.2}% 6
\BOOKMARK [1][-]{section.4.2}{Comparison of synthetic lethal gene candidates}{chapter.4}% 7
\BOOKMARK [2][-]{subsection.4.2.1}{Comparison with siRNA screen candidates}{section.4.2}% 8
\BOOKMARK [3][-]{subsubsection.4.2.1.1}{Comparison with correlation}{subsection.4.2.1}% 9
\BOOKMARK [3][-]{subsubsection.4.2.1.2}{Comparison with viability}{subsection.4.2.1}% 10
\BOOKMARK [3][-]{subsubsection.4.2.1.3}{Comparison with secondary siRNA screen candidates}{subsection.4.2.1}% 11
\BOOKMARK [3][-]{subsubsection.4.2.1.4}{Comparison of screen at pathway level}{subsection.4.2.1}% 12
\BOOKMARK [4][-]{subsubsubsection.4.2.1.4.1}{Resampling of genes for pathway enrichment}{subsubsection.4.2.1.4}% 13
\BOOKMARK [1][-]{section.4.3}{Metagene Analysis}{chapter.4}% 14
\BOOKMARK [2][-]{subsection.4.3.1}{Pathway expression}{section.4.3}% 15
\BOOKMARK [2][-]{subsection.4.3.2}{Somatic mutation}{section.4.3}% 16
\BOOKMARK [2][-]{subsection.4.3.3}{Mutation locus}{section.4.3}% 17
\BOOKMARK [2][-]{subsection.4.3.4}{Synthetic lethal metagenes}{section.4.3}% 18
\BOOKMARK [1][-]{section.4.4}{Replication in stomach cancer}{chapter.4}% 19
\BOOKMARK [2][-]{subsection.4.4.1}{Synthetic Lethal Genes and Pathways}{section.4.4}% 20
\BOOKMARK [2][-]{subsection.4.4.2}{Synthetic Lethal Expression Profiles}{section.4.4}% 21
\BOOKMARK [2][-]{subsection.4.4.3}{Comparison to Primary Screen}{section.4.4}% 22
\BOOKMARK [3][-]{subsubsection.4.4.3.1}{Resampling Analysis}{subsection.4.4.3}% 23
\BOOKMARK [2][-]{subsection.4.4.4}{Metagene Analysis}{section.4.4}% 24
\BOOKMARK [1][-]{section.4.5}{Global Synthetic Lethality}{chapter.4}% 25
\BOOKMARK [2][-]{subsection.4.5.1}{Hub Genes}{section.4.5}% 26
\BOOKMARK [2][-]{subsection.4.5.2}{Hub Pathways}{section.4.5}% 27
\BOOKMARK [1][-]{section.4.6}{Replication in cell line encyclopaedia}{chapter.4}% 28
\BOOKMARK [1][-]{section.4.7}{Discussion}{chapter.4}% 29
\BOOKMARK [2][-]{subsection.4.7.1}{Strengths of the SLIPT Methodology}{section.4.7}% 30
\BOOKMARK [2][-]{subsection.4.7.2}{Syntheic Lethal Pathways for E-cadherin}{section.4.7}% 31
\BOOKMARK [2][-]{subsection.4.7.3}{Replication and Validation}{section.4.7}% 32
\BOOKMARK [3][-]{subsubsection.4.7.3.1}{Integration with siRNA Screening}{subsection.4.7.3}% 33
\BOOKMARK [3][-]{subsubsection.4.7.3.2}{Replication across Tissues and Cell lines}{subsection.4.7.3}% 34
\BOOKMARK [1][-]{section.4.8}{Summary}{chapter.4}% 35
\BOOKMARK [0][-]{section*.40}{References}{}% 36
